Report Code: CMI45749

Published Date: April 2024

Pages: 320+

Category: India

Report Snapshot

CAGR: 11.09%

Source: CMI

Study Period: 2024-2033
Fastest Growing Market: India
Largest Market: India

Major Players

  • Serum Institute of India
  • Biocon Ltd.
  • Panacea Biotech Ltd.
  • Bharat Serums and Vaccines Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Others

Exclusive, in-depth market intelligence can help you increase your Revenue.

Download Sample Pdf

Reports Description

India Biotechnology Market was valued at USD 101.5 Billion in 2024 and is expected to reach USD 297.2 Billion by 2033, at a CAGR of 11.09% during the forecast period 2024 – 2033.

Biotechnology is essentially the use of living organisms and their processes to develop products or technologies. This can involve using bacteria to produce medicines, engineering crops to be more resistant to disease, or even creating new materials with unique properties.

The biotechnology market is booming, expected to reach over $4 trillion by 2033. This growth is driven by factors like rising awareness of health issues, advancements in areas like gene editing, and increased government funding for research.

The market itself is segmented into different areas like biopharmaceuticals, which include drugs and vaccines, and bio agriculture, which focuses on improving crops. There’s also bioinformatics, which uses computer science to analyse biological data, and bio services, which encompasses things like contract research.

India Biotechnology Market: Growth Factors

Government Initiatives and Supportive Policies

The Indian government has been actively promoting biotechnology through various initiatives and policies. The Department of Biotechnology (DBT) has been instrumental in driving research, innovation, and entrepreneurship in the sector. One significant initiative is the Biotechnology Industry Research Assistance Council (BIRAC), which supports startups and SMEs in biotechnology.

According to data from the Ministry of Science & Technology, the government allocated approximately USD 1.1 billion for biotechnology-related programs in the 2021-22 fiscal year, demonstrating strong financial backing for the sector. This support fosters a conducive environment for biotech companies to thrive, driving market growth.

Increasing R&D Investments and Collaboration

India has witnessed a surge in research and development investments in the biotechnology sector. Both public and private entities are allocating substantial funds to advance biotech research and innovation. Additionally, collaborations between Indian biotech firms and international counterparts have intensified, leading to knowledge exchange, technology transfer, and joint ventures.

For instance, partnerships between Indian and global pharmaceutical companies for drug discovery and development are becoming more common. Such collaborations not only accelerate product development but also enhance India’s position in the global biotechnology landscape.

According to the Ministry of Commerce & Industry, India’s R&D expenditure in biotechnology reached approximately INR USD 3 billion in the fiscal year 2020-21, underscoring the growing investment in innovation.

India Biotechnology Market: Restraints

Regulatory Challenges and Approval Delays

Despite government support, the Indian biotechnology market faces regulatory hurdles and delays in product approvals. Stringent regulatory requirements often result in lengthy approval processes, hindering the timely introduction of biotech products into the market.

Complex regulatory frameworks, especially for genetically modified organisms (GMOs) and biopharmaceuticals, pose challenges for companies seeking commercialization. These bottlenecks not only increase operational costs but also impede innovation and market growth.

According to industry reports from the Federation of Indian Chambers of Commerce & Industry (FICCI), regulatory compliance issues contribute to significant delays in product launches, affecting market expansion.

Limited Infrastructure and Skilled Workforce

Despite advancements, India’s biotechnology sector grapples with infrastructural inadequacies and a shortage of skilled professionals. Insufficient laboratory facilities, inadequate manufacturing capacities, and a lack of state-of-the-art infrastructure hamper the scale-up and commercialization of biotech products.

Moreover, the shortage of trained scientists, technicians, and researchers poses a challenge to industry growth. The need for specialized skills in areas such as genomics, bioinformatics, and molecular biology remains unmet, affecting the sector’s competitiveness.

Data from the National Skill Development Corporation (NSDC) indicate that the biotechnology sector faces a skilled workforce gap of over 20%, highlighting the urgent need for capacity building and talent development initiatives.

India Biotechnology Market 2024–2033 (By Application)

India Biotechnology Market: Opportunities

Growing Biopharmaceuticals and Bioinformatics Sector

India’s biopharmaceutical industry is witnessing rapid growth, driven by increasing healthcare expenditure, a large patient pool, and supportive government initiatives such as the National Biopharma Mission.

According to the Department of Biotechnology, Government of India, the biopharmaceutical market in India was valued at approximately $4.4 billion in 2020, and it is expected to reach $12.8 billion by 2025, representing a CAGR of 23%. Further India is emerging as a hub for bioinformatics, leveraging its skilled workforce and advanced IT infrastructure.

The Bioinformatics Industry in India is projected to grow significantly, supported by government initiatives like the Biotechnology Information System Network, leading to collaborations between biotech and IT sectors. The Indian Bioinformatics market was valued at $510 Billion in 2020, and it is expected to surpass $1 billion by 2025, indicating substantial opportunities in this niche segment.

Biotechnology Research and Development

India boasts a strong base of scientific talent and research infrastructure, fostering innovation in biotechnology. The country’s expenditure on R&D in biotechnology has been steadily increasing. As per the Department of Biotechnology, India’s biotechnology research expenditure reached approximately $2.9 billion in 2021, demonstrating a commitment to innovation and technological advancement.

India Biotechnology Market: Segmentation Analysis

India Biotechnology market is segmented by technology and application.

Based on technology, India Biotechnology Market is segmented into Tissue Engineering and Regenerative Medicine, Cell Based Assays, Chromatography, Polymerase Chain Reaction Technology (PCR), DNA Sequencing, Nanobiotechnology, Fermentation, and Others. Among all these segments, Tissue Engineering and Regenerative Medicine held the highest market share in 2023.

Tissue engineering and regenerative medicine are at the forefront of biotechnological advancements, offering potential solutions for various medical conditions, including organ failure and tissue damage. This segment is often supported by significant research funding and interest from both academia and industry.

Nanobiotechnology is rapidly gaining traction due to its interdisciplinary nature, combining nanotechnology and biotechnology to create innovative solutions for drug delivery, diagnostics, and other healthcare applications. The potential for precise targeting and enhanced efficacy makes it a promising area for growth.

Based on technology, India Biotechnology Market is segmented into Healthcare Biotechnology, Agricultural Biotechnology, Industrial Biotechnology, and Environmental Biotechnology. Among all these segments, Healthcare Biotechnology held the highest market share in 2023.

Healthcare biotechnology encompasses a wide range of applications such as pharmaceuticals, diagnostics, personalized medicine, and medical devices. With increasing healthcare expenditure and the demand for advanced medical solutions in India, this segment tends to lead due to its direct impact on improving human health.

Agricultural biotechnology plays a crucial role in addressing food security challenges, increasing crop yield, and developing pest-resistant crops. With the growing population and the need for sustainable agriculture practices in India, there is a rising demand for biotechnological interventions in the agricultural sector, making this subsegment the fastest-growing one.

Report Scope

Feature of the Report Details
Market Size in 2024 USD 101.5 Billion
Projected Market Size in 2033 USD 297.2 Billion
Market Size in 2023 USD 91 Billion
CAGR Growth Rate 11.09% CAGR
Base Year 2023
Forecast Period 2024-2033
Key Segment By Technology, Application and Region
Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Country Scope India
Buying Options Request tailored purchasing options to fulfil your requirements for research.

India Biotechnology Market: Regional Analysis

India’s biotechnology market is witnessing dynamic growth, fueled by various regional factors. In southern India, particularly in Bangalore and Hyderabad, the presence of numerous biotech parks, research institutes, and academic institutions like the Indian Institute of Science and the Centre for Cellular and Molecular Platforms (C-CAMP) fosters a vibrant ecosystem for biotech innovation.

Additionally, the favorable regulatory environment and government initiatives such as the Biotechnology Industry Research Assistance Council (BIRAC) further stimulate growth.

Moving to western India, Maharashtra emerges as a key player with Mumbai and Pune housing prominent biotech clusters. Mumbai’s focus on pharmaceuticals and Pune’s strength in research and development contribute significantly to the region’s biotech landscape. The state’s proactive approach to promoting biotech through incentives and infrastructure development enhances its attractiveness for biotech investments.

In northern India, the National Capital Region (NCR) stands out with its growing biotech presence, driven by initiatives like the Biotech Park in Faridabad and research institutions in Delhi. Government collaborations and investment incentives in states like Uttar Pradesh and Haryana further bolster the region’s biotech potential.

Eastern India, although emerging, shows promise with initiatives like the Kolkata Biotech Park and the biotech ecosystem developing in Odisha. However, infrastructure development and investment in R&D are imperative for unlocking the region’s full biotech potential. Overall, India’s biotechnology market reflects a diverse landscape shaped by regional strengths and collaborative efforts driving innovation and growth.

India Biotechnology Market 2024–2033 (By Billion)

India Biotechnology Market: Recent Developments

  • In December 2023, Reliance Life Sciences received USFDA approval for a generic Insulin Glargine injection. This marks a significant development for India’s biosimilars industry. Reliance’s affordable version of Lantus (Insulin Glargine) can potentially increase access to this critical diabetes medication for patients in India and abroad.
  • In November 2023, Bharat Biotech announced successful Phase 3 trials for its chikungunya vaccine. This indigenous vaccine offers hope for preventing chikungunya, a mosquito-borne viral infection prevalent in India. The successful trials pave the way for regulatory approval and potentially a major public health intervention.
  • In October 2023, Biocon signed strategic partnership with Merck for biosimilar development. This collaboration between a leading Indian biotech firm and a global pharma giant signifies a trend of international recognition for Indian capabilities. The partnership focuses on developing and commercializing biosimilars for global markets.
  • In September 2023, Government of India launched Mission Biotechnology 2.0. This initiative aims to further accelerate India’s biotech sector by promoting innovation, research, and entrepreneurship. The mission focuses on areas like affordable healthcare, biomanufacturing, and bioagriculture.
  • In August 2023, Strand Genomics raised $25 Billion in Series C funding. This funding round reflects the growing investor confidence in Indian biotech startups. Strand Genomics, a precision oncology company, will utilize these funds to advance its liquid biopsy technology for early cancer detection.

List of the prominent players in the India Biotechnology Market:

  • Serum Institute of India
  • Biocon Ltd.
  • Panacea Biotech Ltd.
  • Bharat Serums and Vaccines Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Shanta Biotechnics Limited
  • Cipla Ltd
  • Sun Pharmaceutical Industries Ltd.
  • Zydus Cadila Healthcare Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Divis Laboratories Ltd.
  • Jubilant Life Sciences Ltd.
  • Aurobindo Pharma Ltd.
  • Cadila Healthcare Ltd.
  • Intas Pharmaceuticals Ltd.
  • Strides Shasun Ltd.
  • Ajanta Pharma Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Lupin Ltd.
  • Piramal Enterprises Ltd.
  • Others

These key players are adopting various organic and inorganic growth strategies such as mergers & acquisitions, joint ventures, expansion, strategic alliances, new product launches, etc. to enhance their business operations and revenues.

The India Biotechnology Market is segmented as follows:

By Technology

  • Tissue Engineering and Regenerative Medicine
  • Cell Based Assays
  • Chromatography
  • Polymerase Chain Reaction Technology (PCR)
  • DNA Sequencing
  • Nanobiotechnology
  • Fermentation
  • Others

By Application

  • Healthcare Biotechnology
  • Agricultural Biotechnology
  • Industrial Biotechnology
  • Environmental Biotechnology

Table of Contents

  • Chapter 1. Preface
    • 1.1 Report Description and Scope
    • 1.2 Research scope
    • 1.3 Research methodology
      • 1.3.1 Market Research Type
      • 1.3.2 Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1 India Biotechnology Market, (2024 – 2033) (USD Billion)
    • 2.2 India Biotechnology Market: snapshot
  • Chapter 3. India Biotechnology Market – Industry Analysis
    • 3.1 India Biotechnology Market: Market Dynamics
    • 3.2 Market Drivers
      • 3.2.1 Government Initiatives and Supportive Policies
      • 3.2.2 Increasing R&D Investments and Collaboration
    • 3.3 Market Restraints
    • 3.4 Market Opportunities
    • 3.5 Market Challenges
    • 3.6 Porter’s Five Forces Analysis
    • 3.7 Market Attractiveness Analysis
      • 3.7.1 Market Attractiveness Analysis By Technology
      • 3.7.2 Market Attractiveness Analysis By Application
  • Chapter 4. India Biotechnology Market- Competitive Landscape
    • 4.1 Company market share analysis
      • 4.1.1 India Biotechnology Market: Company Market Share, 2023
    • 4.2 Strategic development
      • 4.2.1 Acquisitions & mergers
      • 4.2.2 New Product launches
      • 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4 Research and development and Regional expansion
    • 4.3 Price trend analysis
  • Chapter 5. India Biotechnology Market – Technology Analysis
    • 5.1 India Biotechnology Market Overview: By Technology
      • 5.1.1 India Biotechnology Market Share, By Technology, 2023 and 2033
    • 5.2 Tissue Engineering and Regenerative Medicine
      • 5.2.1 India Biotechnology Market by Tissue Engineering and Regenerative Medicine, 2024 – 2033 (USD Billion)
    • 5.3 Cell Based Assays
      • 5.3.1 India Biotechnology Market by Cell Based Assays, 2024 – 2033 (USD Billion)
    • 5.4 Chromatography
      • 5.4.1 India Biotechnology Market by Chromatography, 2024 – 2033 (USD Billion)
    • 5.5 Polymerase Chain Reaction Technology (PCR)
      • 5.5.1 India Biotechnology Market by Polymerase Chain Reaction Technology (PCR), 2024 – 2033 (USD Billion)
    • 5.6 DNA Sequencing
      • 5.6.1 India Biotechnology Market by DNA Sequencing, 2024 – 2033 (USD Billion)
    • 5.7 Nanobiotechnology
      • 5.7.1 India Biotechnology Market by Nanobiotechnology, 2024 – 2033 (USD Billion)
    • 5.8 Fermentation
      • 5.8.1 India Biotechnology Market by Fermentation, 2024 – 2033 (USD Billion)
    • 5.9 Others
      • 5.9.1 India Biotechnology Market by Others, 2024 – 2033 (USD Billion)
  • Chapter 6. India Biotechnology Market – Application Analysis
    • 6.1 India Biotechnology Market Overview: By Application
      • 6.1.1 India Biotechnology Market Share, By Application, 2023 and 2033
    • 6.2 Healthcare Biotechnology
      • 6.2.1 India Biotechnology Market by Healthcare Biotechnology, 2024 – 2033 (USD Billion)
    • 6.3 Agricultural Biotechnology
      • 6.3.1 India Biotechnology Market by Agricultural Biotechnology, 2024 – 2033 (USD Billion)
    • 6.4 Industrial Biotechnology
      • 6.4.1 India Biotechnology Market by Industrial Biotechnology, 2024 – 2033 (USD Billion)
    • 6.5 Environmental Biotechnology
      • 6.5.1 India Biotechnology Market by Environmental Biotechnology, 2024 – 2033 (USD Billion)
  • Chapter 7. India Biotechnology Market – Regional Analysis
    • 7.1 India Biotechnology Market Regional Overview
    • 7.2 India Biotechnology Market Share, by Region, 2023 & 2033 (USD Billion)
  • Chapter 8. Company Profiles
    • 8.1 Serum Institute of India
      • 8.1.1 Overview
      • 8.1.2 Financials
      • 8.1.3 Product Portfolio
      • 8.1.4 Business Strategy
      • 8.1.5 Recent Developments
    • 8.2 Biocon Ltd.
      • 8.2.1 Overview
      • 8.2.2 Financials
      • 8.2.3 Product Portfolio
      • 8.2.4 Business Strategy
      • 8.2.5 Recent Developments
    • 8.3 Panacea Biotech Ltd.
      • 8.3.1 Overview
      • 8.3.2 Financials
      • 8.3.3 Product Portfolio
      • 8.3.4 Business Strategy
      • 8.3.5 Recent Developments
    • 8.4 Bharat Serums and Vaccines Limited
      • 8.4.1 Overview
      • 8.4.2 Financials
      • 8.4.3 Product Portfolio
      • 8.4.4 Business Strategy
      • 8.4.5 Recent Developments
    • 8.5 Dr. Reddy’s Laboratories Ltd.
      • 8.5.1 Overview
      • 8.5.2 Financials
      • 8.5.3 Product Portfolio
      • 8.5.4 Business Strategy
      • 8.5.5 Recent Developments
    • 8.6 Shanta Biotechnics Limited
      • 8.6.1 Overview
      • 8.6.2 Financials
      • 8.6.3 Product Portfolio
      • 8.6.4 Business Strategy
      • 8.6.5 Recent Developments
    • 8.7 Cipla Ltd
      • 8.7.1 Overview
      • 8.7.2 Financials
      • 8.7.3 Product Portfolio
      • 8.7.4 Business Strategy
      • 8.7.5 Recent Developments
    • 8.8 Sun Pharmaceutical Industries Ltd.
      • 8.8.1 Overview
      • 8.8.2 Financials
      • 8.8.3 Product Portfolio
      • 8.8.4 Business Strategy
      • 8.8.5 Recent Developments
    • 8.9 Zydus Cadila Healthcare Ltd.
      • 8.9.1 Overview
      • 8.9.2 Financials
      • 8.9.3 Product Portfolio
      • 8.9.4 Business Strategy
      • 8.9.5 Recent Developments
    • 8.10 Torrent Pharmaceuticals Ltd.
      • 8.10.1 Overview
      • 8.10.2 Financials
      • 8.10.3 Product Portfolio
      • 8.10.4 Business Strategy
      • 8.10.5 Recent Developments
    • 8.11 Divis Laboratories Ltd.
      • 8.11.1 Overview
      • 8.11.2 Financials
      • 8.11.3 Product Portfolio
      • 8.11.4 Business Strategy
      • 8.11.5 Recent Developments
    • 8.12 Jubilant Life Sciences Ltd.
      • 8.12.1 Overview
      • 8.12.2 Financials
      • 8.12.3 Product Portfolio
      • 8.12.4 Business Strategy
      • 8.12.5 Recent Developments
    • 8.13 Aurobindo Pharma Ltd.
      • 8.13.1 Overview
      • 8.13.2 Financials
      • 8.13.3 Product Portfolio
      • 8.13.4 Business Strategy
      • 8.13.5 Recent Developments
    • 8.14 Cadila Healthcare Ltd.
      • 8.14.1 Overview
      • 8.14.2 Financials
      • 8.14.3 Product Portfolio
      • 8.14.4 Business Strategy
      • 8.14.5 Recent Developments
    • 8.15 Intas Pharmaceuticals Ltd.
      • 8.15.1 Overview
      • 8.15.2 Financials
      • 8.15.3 Product Portfolio
      • 8.15.4 Business Strategy
      • 8.15.5 Recent Developments
    • 8.16 Strides Shasun Ltd.
      • 8.16.1 Overview
      • 8.16.2 Financials
      • 8.16.3 Product Portfolio
      • 8.16.4 Business Strategy
      • 8.16.5 Recent Developments
    • 8.17 Ajanta Pharma Ltd.
      • 8.17.1 Overview
      • 8.17.2 Financials
      • 8.17.3 Product Portfolio
      • 8.17.4 Business Strategy
      • 8.17.5 Recent Developments
    • 8.18 Glenmark Pharmaceuticals Ltd.
      • 8.18.1 Overview
      • 8.18.2 Financials
      • 8.18.3 Product Portfolio
      • 8.18.4 Business Strategy
      • 8.18.5 Recent Developments
    • 8.19 Lupin Ltd.
      • 8.19.1 Overview
      • 8.19.2 Financials
      • 8.19.3 Product Portfolio
      • 8.19.4 Business Strategy
      • 8.19.5 Recent Developments
    • 8.20 Piramal Enterprises Ltd.
      • 8.20.1 Overview
      • 8.20.2 Financials
      • 8.20.3 Product Portfolio
      • 8.20.4 Business Strategy
      • 8.20.5 Recent Developments
    • 8.21 Others.
      • 8.21.1 Overview
      • 8.21.2 Financials
      • 8.21.3 Product Portfolio
      • 8.21.4 Business Strategy
      • 8.21.5 Recent Developments
List Of Figures

Figures No 1 to 21

List Of Tables

Tables No 1 to 2

Report Methodology

In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:

Preliminary Data Mining

On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.

Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.

Statistical Model

Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.

Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.

Some of the variables taken into account for forecasting are as follows:

• Industry drivers and constraints, as well as their current and projected impact

• The raw material case, as well as supply-versus-price trends

• Current volume and projected volume growth through 2033

We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.

Primary Validation

This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.

Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.

All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:

• Market leaders

• Suppliers of raw materials

• Suppliers of raw materials

• Buyers.

The following are the primary research objectives:

• To ensure the accuracy and acceptability of our data.

• Gaining an understanding of the current market and future projections.

Data Collection Matrix

Perspective Primary research Secondary research
  • Manufacturers
  • Technology distributors and wholesalers
  • Company reports and publications
  • Government publications
  • Independent investigations
  • Economic and demographic data
  • End-user surveys
  • Consumer surveys
  • Mystery shopping
  • Case studies
  • Reference customers

Market Analysis Matrix

Qualitative analysis Quantitative analysis
  • Industry landscape and trends
  • Market dynamics and key issues
  • Technology landscape
  • Market opportunities
  • Porter’s analysis and PESTEL analysis
  • Competitive landscape and component benchmarking
  • Policy and regulatory scenario
  • Market revenue estimates and forecast up to 2033
  • Market revenue estimates and forecasts up to 2033, by technology
  • Market revenue estimates and forecasts up to 2033, by application
  • Market revenue estimates and forecasts up to 2033, by type
  • Market revenue estimates and forecasts up to 2033, by component
  • Regional market revenue forecasts, by technology
  • Regional market revenue forecasts, by application
  • Regional market revenue forecasts, by type
  • Regional market revenue forecasts, by component

Prominent Player

  • Serum Institute of India
  • Biocon Ltd.
  • Panacea Biotech Ltd.
  • Bharat Serums and Vaccines Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Shanta Biotechnics Limited
  • Cipla Ltd
  • Sun Pharmaceutical Industries Ltd.
  • Zydus Cadila Healthcare Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Divis Laboratories Ltd.
  • Jubilant Life Sciences Ltd.
  • Aurobindo Pharma Ltd.
  • Cadila Healthcare Ltd.
  • Intas Pharmaceuticals Ltd.
  • Strides Shasun Ltd.
  • Ajanta Pharma Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Lupin Ltd.
  • Piramal Enterprises Ltd.
  • Others


The Regulatory Challenges and Approval Delays is major restraint in India Biotechnology market.

The Increasing R&D Investments and Collaboration is major driver in India Biotechnology market.

The “Healthcare Biotechnology” had the largest share in the market for India Biotechnology.

The “Tissue Engineering and Regenerative Medicine” category dominated the market in 2023.

The key players in the market are Serum Institute of India, Biocon Ltd., Panacea Biotech Ltd., Bharat Serums and Vaccines Limited, Dr. Reddy’s Laboratories Ltd., Shanta Biotechnics Limited, Cipla Ltd, Sun Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Ltd., Torrent Pharmaceuticals Ltd., Divis Laboratories Ltd., Jubilant Life Sciences Ltd., Aurobindo Pharma Ltd., Cadila Healthcare Ltd., Intas Pharmaceuticals Ltd., Strides Shasun Ltd., Ajanta Pharma Ltd., Glenmark Pharmaceuticals Ltd., Lupin Ltd., Piramal Enterprises Ltd., Others.

The market is projected to grow at a CAGR of 11.09% during the forecast period, 2024-2033.

The India Biotechnology Market size was valued at USD 101.5 Billion in 2024.












What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • Free 25% or 40 hours of customisation.
  • Free post-sale service assistance.
  • 15% discount on your next purchase.
  • Dedicated account Associate .
  • Permission to print the report.
  • Service guarantee available.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • Free 35% or 60 hours of customisation.
  • Free post-sale service assistance.
  • 25% discount on your next purchase.
  • Service guarantee available.
  • Personalised market brief by author.
  • Permission to print the report.
  • Report in your Language.
  • PDF, Excel and Power Point.
  • Can be accessible by unlimited users.
  • Free 40% or 80 hours of customisation.
  • Free post-sale service assistance.
  • 30% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account manager.
  • Service guarantee available.
  • Report in your Language.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
  • 15% discount on your next purchase.
  • Free 20% or 10 hours of customisation.
  • In-Depth Company Profiles.
  • SWOT Analysis.
  • Identify your Competitors.
  • Recent Development Analysis.
  • Competitor Pricing Strategies.
  • Competitor Marketing Strategies.
  • Competitor Positioning and Messaging.
  • Competitor Product’s Strengths.
  • Free 20% or 10 Hours of Customisation.
  • 15% Discount on your Next Purchase.
  • Upgradable to other licenses.
  • PDF Format.
  • Permission to Print the Report.

Want to customize this report?